Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $431.57 | 10 | 97.1% |
| Education | $12.70 | 1 | 2.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $235.85 | 5 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $114.58 | 1 | $0 (2019) |
| Allergan Inc. | $34.93 | 2 | $0 (2019) |
| Gilead Sciences, Inc. | $25.74 | 1 | $0 (2017) |
| AbbVie Inc. | $19.56 | 1 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $13.61 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $19.56 | 1 | AbbVie Inc. ($19.56) |
| 2019 | $178.57 | 5 | Takeda Pharmaceuticals U.S.A., Inc. ($114.58) |
| 2018 | $95.40 | 3 | Merck Sharp & Dohme Corporation ($81.79) |
| 2017 | $150.74 | 2 | Merck Sharp & Dohme Corporation ($125.00) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/16/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/11/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/11/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/19/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/25/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/06/2019 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $114.58 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/27/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/22/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $68.10 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/02/2018 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA, SIVEXTRO | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/17/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/28/2017 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.74 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 973 | 1,814 | $349,695 | $140,719 |
| 2022 | 4 | 815 | 1,530 | $288,878 | $110,930 |
| 2020 | 5 | 307 | 429 | $87,001 | $32,887 |
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 332 | 882 | $128,338 | $55,095 | 42.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 238 | 271 | $111,789 | $37,221 | 33.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 173 | 337 | $70,507 | $31,644 | 44.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 157 | 248 | $19,728 | $9,677 | 49.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 59 | 61 | $17,147 | $6,299 | 36.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 15 | $2,186 | $781.95 | 35.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 306 | 826 | $120,431 | $46,549 | 38.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 242 | 266 | $109,874 | $41,757 | 38.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 110 | 182 | $38,191 | $14,715 | 38.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 157 | 256 | $20,383 | $7,909 | 38.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 146 | 158 | $45,273 | $17,072 | 37.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 81 | 159 | $24,823 | $9,203 | 37.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 42 | 63 | $9,460 | $3,634 | 38.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 18 | 23 | $4,977 | $1,991 | 40.0% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 20 | 26 | $2,467 | $986.96 | 40.0% |
About Dr. Geeti Dhillon, MD
Dr. Geeti Dhillon, MD is a Internal Medicine healthcare provider based in Salisbury, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/08/2012. The National Provider Identifier (NPI) number assigned to this provider is 1427305598.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Geeti Dhillon, MD has received a total of $444.27 in payments from pharmaceutical and medical device companies, with $19.56 received in 2021. These payments were reported across 11 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($431.57).
As a Medicare-enrolled provider, Dhillon has provided services to 2,095 Medicare beneficiaries, totaling 3,773 services with total Medicare billing of $284,535. Data is available for 3 years (2020–2023), covering 15 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location Salisbury, MD
- Active Since 08/08/2012
- Last Updated 06/22/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1427305598
Products in Payments
- ZEPATIER (Drug) $125.00
- ENTYVIO (Biological) $114.58
- ZERBAXA (Drug) $97.16
- AVYCAZ (Drug) $34.93
- DALVANCE (Drug) $19.56
- CUBICIN RF (Drug) $13.69
- XARELTO (Drug) $13.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Salisbury
Akhil Parashar, M.d, M.D
Internal Medicine — Payments: $48,967
Stacy Kennedy, M.d, M.D
Internal Medicine — Payments: $26,914
Dr. Robert Mcneill, M.d, M.D
Internal Medicine — Payments: $14,247
Karim Arnaout, M.d, M.D
Internal Medicine — Payments: $8,657
Dr. David Bearss, M.d, M.D
Internal Medicine — Payments: $7,098
Dr. Justin Kucinski, Do, DO
Internal Medicine — Payments: $7,018